Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Highlights - October 2016


We continue to expand our in silico technology and this month released DDI-Fusion which predicts human drug-drug interactions from structural information and in vitro data. The new addition complements our existing chemPK™, chemTox and chemTarget products as early prediction tools.

We had a strong presence at ELRIG in Liverpool on 13-14 October 2016. Our Head of Toxicology, Dr Paul Walker, and Senior Research Scientist, Dr Stephanie Ryder, were speakers at the event and gave presentations on our latest 3D research at Cyprotex. In October, we also presented posters at the DMDG meeting and ESTIV congress.

Find out more about DDI-Fusion or download our research below
DDI-Fusion — new human DDI predictor

DDI-Fusion is the latest addition to Cyprotex's prediction technology. The new predictor utilizes in vitro data combined with structural information to predict human DDI.

Find out more

in silico prediction
ELRIG 10th Anniversary Drug Discovery 2016, Liverpool, UK

Dr Paul Walker and Dr Stephanie Ryder presented on Cyprotex’s latest 3D cell-based research at ELRIG on 13th and 14th October 2016.

'Confocal high content screening of cardiac and liver microtissues for the improved prediction of drug induced toxicity' (Dr Paul Walker)  

Download the slides

'3D multiplexed high content screening (HCS) of human derived microtissue models for the improved in vitro prediction of toxicity (Dr Stephanie Ryder)'

Download the slides

3D microtissue research
2nd DMDG / GMP Open Meeting, Paris, France

Cyprotex’s Senior Research Scientist, Rachel Upcott-Gill, presented a poster on our research in skin metabolism at the DMDG meeting on 19-21 October 2016.

Download the poster
In vitro skin metabolism
19th International Congress on In Vitro Toxicology ESTIV 2016, Juan-les-Pils, France

Dr Bodo Spori from Cyprotex presented a poster on the development and testing of the short time exposure (STE) model for serious eye damage and ocular irritation as part of the CON4EI consortium.

Download the poster
CON4EI - Short Time Exposure (STE) assay
EU-ToxRisk / Tox21 Collaboration

Last month, it was announced that two initiatives, EU-ToxRisk and US Tox21, would collaborate in their efforts to develop non-animal testing methods for the assessment of chemical safety. Cyprotex play a major role in the EU-ToxRisk consortium.

Read the blog
EU-ToxRisk / Tox21 Collaboration
Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.